BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brudvik KW, Paulsen JE, Aandahl EM, Roald B, Taskén K. Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice. Mol Cancer 2011;10:149. [PMID: 22168384 DOI: 10.1186/1476-4598-10-149] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Lone AM, Giansanti P, Jørgensen MJ, Gjerga E, Dugourd A, Scholten A, Saez-Rodriguez J, Heck AJR, Taskén K. Systems approach reveals distinct and shared signaling networks of the four PGE2 receptors in T cells. Sci Signal 2021;14:eabc8579. [PMID: 34609894 DOI: 10.1126/scisignal.abc8579] [Reference Citation Analysis]
2 Zhang M, Mahoney E, Zuo T, Manchanda PK, Davuluri RV, Kirschner LS. Protein kinase A activation enhances β-catenin transcriptional activity through nuclear localization to PML bodies. PLoS One 2014;9:e109523. [PMID: 25299576 DOI: 10.1371/journal.pone.0109523] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
3 Tai D, Wells K, Arcaroli J, Vanderbilt C, Aisner DL, Messersmith WA, Lieu CH. Targeting the WNT Signaling Pathway in Cancer Therapeutics. Oncologist 2015;20:1189-98. [PMID: 26306903 DOI: 10.1634/theoncologist.2015-0057] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 10.1] [Reference Citation Analysis]
4 Ren LL, Zhou JY, Liang SJ, Wang XQ. Impaired intestinal stem cell activity in ETEC infection: enterotoxins, cyclic nucleotides, and Wnt signaling. Arch Toxicol 2022. [PMID: 35226135 DOI: 10.1007/s00204-021-03213-x] [Reference Citation Analysis]
5 Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016;99:141-149. [PMID: 26775730 DOI: 10.1016/j.critrevonc.2015.12.005] [Cited by in Crossref: 196] [Cited by in F6Publishing: 198] [Article Influence: 28.0] [Reference Citation Analysis]
6 Tafrihi M, Nakhaei Sistani R. E-Cadherin/β-Catenin Complex: A Target for Anticancer and Antimetastasis Plants/Plant-derived Compounds. Nutr Cancer 2017;69:702-22. [PMID: 28524727 DOI: 10.1080/01635581.2017.1320415] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
7 Jansen SR, Poppinga WJ, de Jager W, Lezoualc'h F, Cheng X, Wieland T, Yarwood SJ, Gosens R, Schmidt M. Epac1 links prostaglandin E2 to β-catenin-dependent transcription during epithelial-to-mesenchymal transition. Oncotarget 2016;7:46354-70. [PMID: 27344171 DOI: 10.18632/oncotarget.10128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
8 Duchartre Y, Kim YM, Kahn M. Pharmacologic Manipulation of Wnt Signaling and Cancer Stem Cells. Methods Mol Biol 2017;1613:463-78. [PMID: 28849572 DOI: 10.1007/978-1-4939-7027-8_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Singleton DC, Harris AL. Targeting the ATF4 pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012;16:1189-202. [DOI: 10.1517/14728222.2012.728207] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 6.7] [Reference Citation Analysis]
10 Namani A, Li J, Wang XJ, Tang X. A Review of Compounds for Prevention of Colorectal Cancer. Curr Pharmacol Rep 2017;3:221-31. [DOI: 10.1007/s40495-017-0101-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
11 Jansen S, Gosens R, Wieland T, Schmidt M. Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharmacol Ther 2018;183:1-21. [PMID: 28911825 DOI: 10.1016/j.pharmthera.2017.09.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 14.8] [Reference Citation Analysis]
12 Sánchez-Tena S, Reyes-Zurita FJ, Díaz-Moralli S, Vinardell MP, Reed M, García-García F, Dopazo J, Lupiáñez JA, Günther U, Cascante M. Maslinic acid-enriched diet decreases intestinal tumorigenesis in Apc(Min/+) mice through transcriptomic and metabolomic reprogramming. PLoS One 2013;8:e59392. [PMID: 23527181 DOI: 10.1371/journal.pone.0059392] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
13 Zhang H, Kong Q, Wang J, Jiang Y, Hua H. Complex roles of cAMP-PKA-CREB signaling in cancer. Exp Hematol Oncol 2020;9:32. [PMID: 33292604 DOI: 10.1186/s40164-020-00191-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
14 Guo H, Nagy T, Pierce M. Post-translational glycoprotein modifications regulate colon cancer stem cells and colon adenoma progression in Apc(min/+) mice through altered Wnt receptor signaling. J Biol Chem. 2014;289:31534-31549. [PMID: 25274627 DOI: 10.1074/jbc.m114.602680] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
15 Chen Z, Xue C. G-Protein-Coupled Receptor 5 (LGR5) Overexpression Activates β-Catenin Signaling in Breast Cancer Cells via Protein Kinase A. Med Sci Monit Basic Res 2019;25:15-25. [PMID: 30662060 DOI: 10.12659/MSMBR.912411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
16 Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ruud E, Naderi S, Blomhoff HK. Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death. Mol Cancer 2015;14:14. [PMID: 25623255 DOI: 10.1186/s12943-014-0278-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
17 Lone AM, Taskén K. Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol 2013;4:130. [PMID: 23760108 DOI: 10.3389/fimmu.2013.00130] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
18 Scott JD, Dessauer CW, Taskén K. Creating order from chaos: cellular regulation by kinase anchoring. Annu Rev Pharmacol Toxicol 2013;53:187-210. [PMID: 23043438 DOI: 10.1146/annurev-pharmtox-011112-140204] [Cited by in Crossref: 133] [Cited by in F6Publishing: 127] [Article Influence: 13.3] [Reference Citation Analysis]
19 Wehbi VL, Taskén K. Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units. Front Immunol 2016;7:222. [PMID: 27375620 DOI: 10.3389/fimmu.2016.00222] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 13.7] [Reference Citation Analysis]
20 Jansen SR, Holman R, Hedemann I, Frankes E, Elzinga CR, Timens W, Gosens R, de Bont ES, Schmidt M. Prostaglandin E2 promotes MYCN non-amplified neuroblastoma cell survival via β-catenin stabilization. J Cell Mol Med 2015;19:210-26. [PMID: 25266063 DOI: 10.1111/jcmm.12418] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
21 Yaqub S, Bjørnbeth BA, Angelsen JH, Fristrup CW, Grønbech JE, Hemmingsson O, Isaksson B, Juel IS, Larsen PN, Lindell G, Mortensen FV, Mortensen KE, Rizell M, Sandström P, Sandvik OM, Sparrelid E, Taflin H, Taskén K; ASAC study group. Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial. Trials 2021;22:642. [PMID: 34544470 DOI: 10.1186/s13063-021-05587-w] [Reference Citation Analysis]
22 Chu HS, Peterson C, Jun A, Foster J. Targeting the integrated stress response in ophthalmology. Curr Eye Res 2021;46:1075-88. [PMID: 33474991 DOI: 10.1080/02713683.2020.1867748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Choi HK, Yoo JY, Jeong MH, Park SY, Shin DM, Jang SW, Yoon HG, Choi KC. Protein kinase A phosphorylates NCoR to enhance its nuclear translocation and repressive function in human prostate cancer cells. J Cell Physiol. 2013;228:1159-1165. [PMID: 23129261 DOI: 10.1002/jcp.24269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
24 Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases (Review). Int J Mol Med. 2017;40:587-606. [PMID: 28731148 DOI: 10.3892/ijmm.2017.3071] [Cited by in Crossref: 37] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
25 Slattery ML, Mullany LE, Sakoda LC, Samowitz WS, Wolff RK, Stevens JR, Herrick JS. Expression of Wnt-signaling pathway genes and their associations with miRNAs in colorectal cancer. Oncotarget 2018;9:6075-85. [PMID: 29464056 DOI: 10.18632/oncotarget.23636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
26 Li H, Zhang N, Jiao X, Wang C, Sun W, He Y, Ren G, Huang S, Li M, Chang Y, Jin Z, Xie Q, Zhang X, Huang H, Jin H. Downregulation of microRNA-6125 promotes colorectal cancer growth through YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3β. Clin Transl Med 2021;11:e602. [PMID: 34709763 DOI: 10.1002/ctm2.602] [Reference Citation Analysis]
27 Zhang SL, Chen ZH, Lin DT, Yan Q, Gao F, Lin H. Epigallocatechin gallate regulates inflammatory responses and new bone formation through Wnt/β-Catenin/COX-2 pathway in spondyloarthritis. Int Immunopharmacol 2021;98:107869. [PMID: 34153673 DOI: 10.1016/j.intimp.2021.107869] [Reference Citation Analysis]
28 Hussain M, Tang F, Liu J, Zhang J, Javeed A. Dichotomous role of protein kinase A type I (PKAI) in the tumor microenvironment: a potential target for 'two-in-one' cancer chemoimmunotherapeutics. Cancer Lett 2015;369:9-19. [PMID: 26276720 DOI: 10.1016/j.canlet.2015.07.047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
29 Naderi EH, Ugland HK, Diep PP, Josefsen D, Ruud E, Naderi S, Blomhoff HK. Selective inhibition of cell death in malignant vs normal B-cell precursors: implications for cAMP in development and treatment of BCP-ALL. Blood 2013;121:1805-13. [PMID: 23299313 DOI: 10.1182/blood-2012-08-452698] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
30 Hussain M, Shah Z, Abbas N, Javeed A, Mukhtar MM, Zhang J. Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy. Medical Hypotheses 2016;86:56-9. [DOI: 10.1016/j.mehy.2015.11.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Hussain M, Javeed A, Ashraf M, Yuzhu H, Mukhtar MM. Multilevel pharmacological manipulation of adenosine-prostaglandin E₂/cAMP nexus in the tumor microenvironment: a 'two hit' therapeutic opportunity. Pharmacol Res 2013;73:8-19. [PMID: 23619528 DOI: 10.1016/j.phrs.2013.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]